|Mr. Anthony S. Marucci||Founder, Pres, CEO & Director||873.75k||N/A||1962|
|Dr. Tibor Keler Ph.D.||Founder, Chief Scientific Officer and Exec. VP||552.71k||N/A||1959|
|Ms. Elizabeth Crowley||Chief Product Devel. Officer and Sr. VP||423.2k||N/A||1972|
|Mr. Sam Martin||Sr. VP, CFO, Principal Accounting Officer & Treasurer||N/A||N/A||N/A|
|Ms. Sarah Cavanaugh||Sr. VP of Corp. Affairs & Admin.||N/A||N/A||N/A|
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma. The company also develops earlier stage drug candidates that are in clinical development, including CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers; CDX-1140, a human monoclonal antibody; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-1401, an immunotherapeutic aimed at antigen presenting cells for cancer indications. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; Seattle Genetics, Inc.; Yale University; and MedImmune, LLC. The company is headquartered in Hampton, New Jersey.
Celldex Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 3. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 1; Compensation: 6.